These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 607967)

  • 21. Effect of somatostatin (SRIF) on plasma glucose and insulin response to glucagon in liver cirrhosis.
    Altomonte L; Greco AV; Ghirlanda G; Rebuzzi AG; Manna R; Bertoli A
    Acta Diabetol Lat; 1979; 16(2):139-45. PubMed ID: 484163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low serum T3 and raised reverse T3 levels in hepatic cirrhosis: role of glucagon.
    Kabadi UM; Kabadi MU; Premachandra BN
    Am J Gastroenterol; 1991 Oct; 86(10):1504-7. PubMed ID: 1928046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
    Holst JJ; Burcharth F; Kühl C
    Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.
    Sherwin RS; Fisher M; Bessoff J; Snyder N; Hendler R; Conn HO; Felig P
    Gastroenterology; 1978 Jun; 74(6):1224-8. PubMed ID: 648812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Somatostatin plasma level in patients with liver cirrhosis].
    Tulassay Z; Tulassay T; Szabó A; Jaszovszky I; Gohér A
    Orv Hetil; 1995 May; 136(22):1163-5. PubMed ID: 7761079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian variation in glucose tolerance and associated changes in plasma insulin and somatostatin levels in normal volunteers.
    Verrillo A; de Teresa A; Rucco E
    Boll Soc Ital Biol Sper; 1984 Dec; 60(12):2261-6. PubMed ID: 6152172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Somatostatin--a hypothalamic factor inhibiting the secretion of growth hormone].
    Lankosz-Lauterbach J
    Pediatr Pol; 1977 Aug; 52(8):919-23. PubMed ID: 333364
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged suppression of pituitary and pancreatic hormone release by a somatostatin analog.
    Lien EL; Fenichel RL; Grant NH; Boxill GC; Greenwood J; Yardley JP
    Biochem Biophys Res Commun; 1977 Aug; 77(4):1317-25. PubMed ID: 143285
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolic effects of long-term somatostatin infusion in man.
    Gerich JE
    Metabolism; 1976 Nov; 25(11 Suppl 1):1505-7. PubMed ID: 988466
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of synthetic somatostatin on endotoxin-induced changes of growth hormone, cortisol and insulin in plasma, blood sugar and blood leukocytes in man.
    Wagner H; Zierden E; Hauss WH
    Klin Wochenschr; 1975 Jun; 53(11):539-41. PubMed ID: 1152345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose.
    Greco AV; Ghirlanda G; Patrono C; Fedili G; Manna R
    Acta Diabetol Lat; 1974; 11(4):330-9. PubMed ID: 4466304
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of somatostatin on the hormonal abnormalities of end stage renal disease.
    Murray TG; Eisen C; Grabie M; Buerklin E; Walker BR; Goldberg M
    J Int Med Res; 1981; 9(1):1-5. PubMed ID: 6110592
    [No Abstract]   [Full Text] [Related]  

  • 33. Temporal serum concentrations of growth hormone, thyrotropin, insulin, and glucagon in sheep immunized against somatostatin.
    Varner MA; Davis SL; Reeves JJ
    Endocrinology; 1980 Mar; 106(3):1027-32. PubMed ID: 6986257
    [No Abstract]   [Full Text] [Related]  

  • 34. Hyperglycemia induced by somatostatin in normal subjects.
    Lins PE; Efendić S
    Horm Metab Res; 1976 Nov; 8(6):497-8. PubMed ID: 1002112
    [No Abstract]   [Full Text] [Related]  

  • 35. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.
    Pimstone BL; Le Roith D; Epstein S; Kronheim S
    J Clin Endocrinol Metab; 1975 Aug; 41(2):392-3. PubMed ID: 1159052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure activity studies on somatostatin.
    Sarantakis D; McKinley WA; Jaunakais I; Clark D; Grant NH
    Clin Endocrinol (Oxf); 1976; 5 Suppl():275S-278S. PubMed ID: 1052780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of glucagon in ascitic fluid in cirrhotic patients.
    Kabadi UM; Uddinn MS; Eisenstein AB
    J Endocrinol Invest; 1983 Jun; 6(3):229-34. PubMed ID: 6352794
    [No Abstract]   [Full Text] [Related]  

  • 38. Somatostatin infusion in liver cirrhosis: glucagon control of glucose homeostasis.
    Greco AV; Altomonte L; Ghirlanda G; Rebuzzi AG; Manna R; Bertoli A
    Diabetologia; 1980 Mar; 18(3):187-91. PubMed ID: 6102941
    [No Abstract]   [Full Text] [Related]  

  • 39. [Significance of glucagon test in liver cirrhosis].
    Kurochka Iu; Shpaniar E; Levchik A; Zagradni V; Golan I
    Klin Med (Mosk); 1977 Nov; 55(11):73-6. PubMed ID: 606995
    [No Abstract]   [Full Text] [Related]  

  • 40. Failure of somatostatin to eliminate the glucagon release induced by baroreceptor unloading in the cat.
    Järhult J; Ahrén B; Ericsson M; Holst J
    Acta Physiol Scand; 1978 Aug; 103(4):478-80. PubMed ID: 716969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.